DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Information source: NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pneumonia, Pneumocystis Carinii; HIV Infections

Intervention: Dapsone (Drug)

Phase: N/A

Status: Completed

Sponsored by: Jacobus Pharmaceutical

Summary

To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3. To determine whether the long-term toxicities associated with daily dapsone in this population are tolerable.

Clinical Details

Official title: Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)

Study design: Primary Purpose: Treatment

Eligibility

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria The patient must have HIV positive antibody test and presence of oral thrush or hairy leukoplakia.

- Patient must be willing and able to sign informed consent.

Exclusion Criteria Co-existing Condition: Patients with the following are excluded:

- Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.

- Prophylaxis for PCP in preceding 3 months.

- Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.

- Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative

dermatitis during treatment with dapsone.

- History of poor compliance.

Concurrent Medication: Excluded:

- Zidovudine (AZT).

Patients with the following are excluded:

- Prior Pneumocystis carinii pneumonia (PCP) or AIDS-defining condition.

- Prophylaxis for PCP in preceding 3 months.

- Absence of detectable glucose-6-phosphate dehydrogenase (G6PD) activity.

- Concurrent or prior therapy with zidovudine (AZT).

- Prior type I hypersensitivity (anaphylaxis, urticaria, angioedema) or exfoliative

dermatitis during treatment with dapsone.

- History of poor compliance.

Prior Medication: Excluded:

- Zidovudine (AZT).

Locations and Contacts

UCLA CARE Ctr, Los Angeles, California 90095, United States
Additional Information


Last updated: June 23, 2005

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017